DOI: https://doi.org/10.30841/2307-5112.5-6.2019.193437

Особенности течения метапневмовирусной инфекции у взрослых

О. К. Дуда, А. Р. Вега, Л. П. Коцюбайло

Аннотация


Цель исследования: установление клинических особенностей течения метапневмовирусной инфекции у взрослых и определение влияние коинфекции на тяжесть течения болезни.

Материалы и методы. Для проведения данного исследования использовали библиосемантический и аналитический методы. Проводили анализ новейших научных публикаций таких электронных баз данных, как PubMed, Skopus, Cochrane.

Результаты. Доля метапневмовирусной инфекции в этиологической структуре ОРВИ составляет от 4 до 13%. Хотя большинство детей инфицируются HMPV еще до 5 лет, однако реинфекция возможна в течение всей взрослой жизни. Так, HMPV был обнаружен у 13% госпитализированных взрослых в Рочестере (штат Нью-Йорк, США). Клинические проявления HMPV-инфекции разнообразны, но чаще всего наблюдают: бронхиолит, пневмония, круп и обострение бронхиальной астмы. Частота возникновения вирусной коинфекции составляет от 6 до 23%.

Заключение. HMPV-инфекция в основном протекает легко у здоровых людей, но инфицирование HMPV в пожилом возрасте на фоне сопутствующей патологии приводит к увеличению тяжести заболевания и повышению заболеваемости и смертности. Коинфекция с другими вирусами или бактериями может привести к ухудшению симптомов и состояния пациента, однако на тяжесть течения заболевания скорее всего не влияет.

Ключевые слова


метапневмовирус; метапневмовирусная инфекция; острая респираторная вирусная инфекция; НМРV

Полный текст:

PDF (Українська)

Литература


van den Hoogen BG, de Jong JC, Groen J, et al.: A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24. 10.1038/89098

Biacchesi S, Skiadopoulos MH, Yang L, et al.: Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol. 2004;78(23):12877–87. 10.1128/JVI.78.23.12877-12887.2004

Chang A, Masante C, Buchholz UJ, et al.: Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol.2012;86(6):3230–43. 10.1128/JVI.06706-11

Derdowski A, Peters TR, Glover N, et al.: Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation. J Gen Virol. 2008;89(Pt 11):2698–708. 10.1099/vir.0.2008/004051-0

Fearns R, Collins PL: Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol. 1999;73(7):5852–64.

Ren J, Wang Q, Kolli D, et al.: Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS. J Virol. 2012;86(23):13049–61. 10.1128/JVI.01248-12

Masante C, El Najjar F, Chang A, et al.: The human metapneumovirus small hydrophobic protein has properties consistent with those of a viroporin and can modulate viral fusogenic activity. J Virol.2014;88(11):6423–33. 10.1128/JVI.02848-13

Thammawat S, Sadlon TA, Hallsworth PG, et al.: Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol. 2008;82(23):11767–74. 10.1128/ JVI.01208-08

Shafagati N, Williams J. Human metapneumovirus – what we know now. F1000Res. 2018; 7:135. Published 2018 Feb 1. doi:10.12688/ f1000 research.12625.1

El Najjar F, Cifuentes-Muñoz N, Chen J, et al.: Human metapneumovirus Induces Reorganization of the Actin Cytoskeleton for Direct Cell-to-Cell Spread. PLoS Pathog. 2016;12(9):e1005922. 10.1371/journal.ppat.1005922

Thammawat S, Sadlon TA, Hallsworth PG, et al.: Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol. 2008;82(23):11767–74. 10.1128/JVI.01208-08

Hamelin ME, Couture C, Sackett M, et al. : The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir Ther. 2008;13(1):39–46

Falsey AR, Hennessey PA, Formica MA, et al. :Humoral immunity to human metapneumovirus infection in adults. Vaccine. 2010;28(6):1477–80. 10.1016/j.vaccine.2009.11.063

van den Hoogen BG, Herfst S, Sprong L, et al. : Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis. 2004;10(4):658–66. 10.3201/eid1004.030393

MacPhail M, Schickli JH, Tang RS, et al. : Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J Gen Virol. 2004;85(Pt 6):1655–63. 10.1099/vir.0.79805-0

Yang CF, Wang CK, Tollefson SJ, et al. : Human metapneumovirus G protein is highly conserved within but not between genetic lineages. Arch Virol. 2013;158(6):1245–52. 10.1007/s00705-013

McDougall JS, Cook JK: Turkey rhinotracheitis: preliminary investigations. Vet Rec. 1986;118(8):206–7. 10.1136/vr.118.8.206

Easton AJ, Domachowske JB, Rosenberg HF: Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev. 2004;17(2):390–412. 10.1128/CMR.17.2.390-412.2004

Juhasz K, Easton AJ: Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups. J Gen Virol. 1994;75(Pt 11):2873–80. 10.1099/0022-1317-75-11-2873

Aberle J.H., Aberle S.W., Redlberger-Fritz M., Sandhofer M.J., Popow-Kraupp T. 2010. Human metapneumovirus subgroup changes and seasonality during epidemics. Pediatr. Infect. Dis. J. 29:1016–1018

Ditt V., Lusebrink J., Tillmann R.L., Schildgen V., Schildgen O. 2011. Respiratory infections by HMPV and RSV are clinically indistinguishable but induce different host response in aged individuals. PLoS One 6:e16314.

Lusebrink J., et al. High seroprevalence of neutralizing capacity against human metapneumovirus in all age groups studied in Bonn, Germany. Clin. Vaccine Immunol. 17:481–484

Williams JV, Edwards KM, Weinberg GA, et al. : Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis. 2010;201(12):1890–8. 10.1086/652782

Walsh EE, Peterson DR, Falsey AR: Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168(22):2489–96. 10.1001/archinte.168.22.2489

Honda H., et al. 2006. Outbreak of human metapneumovirus infection in elderly inpatients in Japan. J. Am. Geriatr. Soc. 54:177–180

Darniot M., Petrella T., Aho S., Pothier P., Manoha C. 2005. Immune response and alteration of pulmonary function after primary human metapneumovirus (hMPV) infection of BALB/c mice. Vaccine23:4473–4480

Vargas S.O., Kozakewich H.P., Perez-Atayde A.R., McAdam A.J. 2004. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr. Dev. Pathol. 7:478–486

Beneri C., Ginocchio C.C., Manji R., Sood S. 2009. Comparison of clinical features of pediatric respiratory syncytial virus and human metapneumovirus infections. Infect. Control Hosp. Epidemiol. 30:1240–1241

Howard LM, Edwards KM, Zhu Y, et al.: Clinical Features of Human Metapneumovirus Infection in Ambulatory Children Aged 5–13 Years. J Pediatric Infect Dis Soc. 2017. 10.1093/jpids/pix012

Williams JV, Harris PA, Tollefson SJ, et al. : Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350(5):443–50. 10.1056/NEJMoa025472

van den Hoogen B.G., Osterhaus D.M., Fouchier R.A. 2004. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr. Infect. Dis. J. 23:S25–S32

Williams JV, Crowe JE, Jr, Enriquez R, et al. :Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis. 2005;192(7):1149–53. 10.1086/444392

Boivin G, Abed Y, Pelletier G, et al. : Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. 2002;186(9):1330–4. 10.1086/344319

Boeckh M., Erard V., Zerr D., Englund J. 2005. Emerging viral infections after hematopoietic cell transplantation. Pediatr. Transplant. 9(Suppl. 7):48–54

Williams J.V., et al. 2005. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J. Infect. Dis.192:1061–1065

Cane P.A., van den Hoogen B.G., Chakrabarti S., Fegan C.D., Osterhaus A.D. 2003. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. 31:309–310

van den Hoogen B.G. 2007. Respiratory tract infection due to human metapneumovirus among elderly patients. Clin. Infect. Dis. 44:1159–1160

Vicente D., Montes M., Cilla G., Perez-Trallero E. 2004. Human metapneumovirus and chronic obstructive pulmonary disease. Emerg. Infect. Dis. 10:1338–1339

Boivin G., et al. 2007. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin. Infect. Dis. 44:1152–1158

Ginocchio C.C., Manji R., Lotlikar M., Zhang F. 2008. Clinical evaluation of NucliSENS magnetic extraction and NucliSENS analyte-specific reagents for realtime detection of human metapneumovirus in pediatric respiratory specimens. J. Clin. Microbiol. 46:1274–1280

Tollefson SJ, Cox RG, Williams JV: Studies of culture conditions and environmental stability of human metapneumovirus. Virus Res. 2010;151(1):54–9. 10.1016/j.virusres.2010.03.018

Wyde P.R., Chetty S.N., Jewell A.M., Boivin G., Piedra P.А. 2003. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 60:51–59




Copyright (c) 2019 Семейная медицина

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter